Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2 diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists (RAs) are currently indicated for T2DM in the USA. Exenatide and liraglutide are short-acting and require twice-daily and daily dosing, respectively. Two longer acting agents, exenatide long-acting release (LAR) and albiglutide, were formulated to allow for once-weekly dosing. All four GLP-1 RAs have demonstrated reductions in hemoglobin A1c, fasting blood glucose, and body weight both as monotherapy and in combination with first-and secondline diabetes agents including metformin, sulfonylureas, thiazolidinediones, and insulin. Greater glycemic control was seen with liraglutide compared with the other GLP-1 treatment options; however, the two long-acting agents were superior to exenatide twice daily. All agents were well tolerated with most adverse events being mild or moderate in nature. The most common adverse event was transient nausea which typically resolved 4-8 weeks after treatment initiation. Long-acting agents had lower rates of nausea but an increased incidence of injection site reactions. Trials have suggested GLP-1 RAs may improve cardiovascular risk factors including blood pressure, lipid parameters and inflammatory markers. Future trials are needed to confirm the clinical outcomes of these agents. Overall, GLP-1 RAs will provide benefit for patients with T2DM intolerable to or not reaching glycemic goals with first-line agents, especially in patients in need of weight loss.
Introduction
Glucagon-like peptide 1 (GLP-1) is an endogenous hormone produced and released by intestinal epithelial endocrine L cells in response to food intake [Holst, 2007; Frias and Edelman, 2007; Nauck et al. 2004] . While the effects of GLP-1, including increased insulin secretion, decreased glucagon secretion, slowed gastric emptying, and maintenance of blood glucose (BG) levels, are maintained, GLP-1 secretion is often reduced in patients with type 2 diabetes mellitus (T2DM) [Holst, 2007; Frias and Edelman, 2007; Nauck et al. 2004; Kreymann et al. 1987; Nauck et al. 1986 ]. When exogenous GLP-1 is administered to patients with T2DM, fasting BG (FBG) is decreased while c-peptide and insulin secretion are increased until BG returns to normal [Nauck et al. 1993; Toft-Nielsen et al. 1999 ]. This glucose-dependent effect reduces the risk of hypoglycemia.
The use of GLP-1 therapy was limited by its rapid breakdown by dipeptidyl peptidase IV (DPP-IV) [Holst, 2006 [Holst, , 2007 . However, several GLP-1 receptor agonists have been discovered that are DPP-IV resistant, making them valuable in diabetes treatment. Exenatide and liraglutide were US Food and Drug Administration (FDA) approved in 2005 and 2010 and are administered subcutaneously twice daily and daily, respectively [Amylin Pharmaceuticals, Inc., 2011; Novo Nordisk A/S, 2013] . In 2012 and 2014, exenatide long-acting release (LAR) and albiglutide were approved. These agents were modified to increase the half life, allowing for once weekly subcutaneous administration [Amylin Pharmaceuticals, Inc., 2012; GlaxoSmithKline LLC, 2014] .
The consensus treatment algorithm from the American Diabetes Association and the European Association for the Study of Diabetes recommends metformin first line for patients diagnosed with T2DM. If metformin does not reach glycemic goals, add-on therapy with either pioglitazone, a sulfonylurea (SU), a DPP-IV inhibitor, a GLP-1 RA, or insulin is recommended. Medication choices should be based on patientspecific conditions considering the effect on glycemic control and body weight, the risk of hypoglycemia and other potential advantages or disadvantages [Inzucchi et al. 2012] . The following sections discuss the efficacy and safety of exenatide, liraglutide, exenatide LAR, and albiglutide and characteristics that may influence their use.
Short-acting GLP-1 RAs
Efficacy Exenatide 5 and 10 μg twice daily as well as liraglutide 0.6 mg, 1.2 mg, and 1.8 mg daily have been studied as monotherapy and in combination with metformin, SUs, thiazolidinediones (TZDs), and insulin. Liraglutide 0.6 mg showed minimal reduction in glycemic parameters and therefore results from the higher doses are reported here. Results from selected trials are summarized in Table 1 .
Exenatide monotherapy lowered hemoglobin A1c (HbA1c) by 0.7-0.9%, FBG by 17.5-18.7 mg/dl (0.97-1.03 mmol/liter) postprandial BG (PBG) excursions by 21.3-24.7 mg/dl (1.18-1.37 mmol/liter). In addition, exenatide monotherapy resulted in body weight reductions of 2.8-3.1 kg [Moretto et al. 2008 ]. In a small study of 58 patients with obesity and newly diagnosed T2DM, exenatide monotherapy compared with metformin monotherapy showed similar reductions in FBG [-32 .4 mg/dl (-1.8 mmol/ liter) versus -28.8 mg/dl (-1.6 mmol/liter)] as well as significantly greater reductions in HbA1c (-2.1% versus -1.66%), 2 h oral glucose tolerance test [-91 .9 mg/dl (-5.1 mmol/liter) versus -50.4 mg/dl (-2.8 mmol/liter)] and body weight (-5 .8 kg versus -3.42 kg) [Yuan et al. 2012] . In 746 patients with T2DM, monotherapy with liraglutide 1.2 and 1.8 mg daily compared with glimepiride 8 mg daily significantly decreased HbA1c (-0.84% and −1.14% versus -0.51%) and FBG [-15.1 and −25.6 mg/dl (-0.84 and −1.42 mmol/liter) versus -5.2 mg/dl (-0.28 mmol/liter)]. Liraglutide also significantly reduced body weight while glimepiride resulted in weight gain [Garber et al. 2009 ]. An extension trial demonstrated continued reductions in HbA1c, FBG, and body weight for 2 years of liraglutide therapy [Garber et al. 2011 ]. Based on these results, exenatide and liraglutide are good first-line options for patients unable to take metformin.
Three 30-week trials evaluated exenatide added to metformin, a SU, and both. Exenatide 5-10 μg twice daily reduced HbA1c, FBG, and body weight by 0.4-0.86%, 5.4-10.8 mg/dl (0.3-0.6 mmol/liter), and 0.9-2.8 kg, respectively [Buse et al. 2004; Kendall et al. 2005; DeFronzo et al. 2005] . Extension trials demonstrated the durability of exenatide added to metformin or SU therapy with sustained reductions in HbA1c and FBG as well as progressive body weight reductions extending for up to 3 years of therapy [Ratner et al. 2006; Buse et al. 2007; Riddle et al. 2006; Blonde et al. 2006; Klonoff et al. 2008] . When stratified by baseline HbA1c, larger reductions in HbA1c were seen in patients with baseline HbA1c greater than 9% [Buse et al. 2004; Kendall et al. 2005; Riddle et al. 2006; Blonde et al. 2006 ]. When directly compared, 26 weeks of liraglutide significantly lowered HbA1c (-1.12% versus -0.79%) and FBG [-28.9 mg/dl (-1.6 mmol/liter) versus -10.8 mg/dl (-0.6 mmol/ liter)] compared with exenatide in 464 patients with uncontrolled T2DM while taking metformin, a SU, or both. Exenatide significantly lowered PBG after breakfast and dinner. Reductions in body weight between groups were similar ]. In combination with a TZD with or without metformin, exenatide significantly lowered HbA1c by 0.8-0.9% and FBG by 14.4-28.6 mg/dl (0.8-1.59 mmol/liter) compared with placebo [Liutkus et al. 2010; Zinman et al. 2007 ]. However, body weight reductions (-1.4 to −1.7 kg) were only significant in one of two trials [Liutkus et al. 2010; Zinman et al. 2007] . Liraglutide added to a TZD and metformin also significantly reduced HbA1c (-1.5% versus -0.5%), FBG [-40 to −44 mg/dl (-2.22 to −2.44 mmol/liter) versus -8 mg/dl (-0.44 mmol/ liter)], body weight (-1 to −2 kg versus +0.6 kg) and 90 min PBG [-47 to −49 mg/dl (-2.61 to −2.72 mmol/liter) versus -14 mg/dl (0.77 mmol/ liter)] compared with placebo [Zinman et al. [Lu et al. 2013; Gao et al. 2009; Kadowaki et al. 2009; Yang et al. 2011] , indicating exenatide and liraglutide provide improvement in glycemic control and body weight in most patients when used in combination with other oral antidiabetic medications (OAMs).
Exenatide and liraglutide have recently been approved for use in combination with long-acting insulin. Two retrospective trials showed a significant decrease in both HbA1c (-0.5% to −0.7%) and body weight (-2.5 to −5.8 kg) when exenatide was added to insulin therapy. Changes in diabetes treatments varied, with one study showing significant decreases in insulin doses (-0.3 U/kg) as well as the proportion of patients taking metformin and SUs while the other showed increases in insulin doses (0.1 U/kg) and no change in oral diabetic therapies [Thong et al. 2011; Levin et al. 2012] . In a randomized, controlled trial including 261 patients, exenatide significantly reduced HbA1c (-1.74 versus -1.04%) and body weight (-1.78 versus +0.96 kg) compared with placebo when added to insulin glargine. FBG reductions were similar between groups [-28.8 versus -27.0 mg/dl (-1.6 versus -1.5 mmol/liter)]; however, PBG excursions were significantly lower after morning and evening meals with exenatide. Insulin doses increased in both groups but increased more in the placebo group (20 versus 13 U/day) [Buse et al. 2011 ]. The addition of insulin detemir to metformin and liraglutide was studied in 988 patients with T2DM. Subjects receiving insulin detemir experienced a decrease in HbA1c of 0.51% compared with an increase of 0.02% with placebo. Although significantly greater with placebo, both groups continued to experience weight loss (-0.16 kg with insulin versus -0.95 kg with placebo) [DeVries et al. 2012 ]. An extension study found reductions in HbA1c were maintained in each group for 52 weeks [Rosenstock et al. 2013b ]. Both therapies showed benefit in combination with insulin and may provide additional PBG reductions.
When compared with oral, add-on therapies, exenatide and liraglutide continued to demonstrate benefit on glycemic control. In combination with metformin, a SU or both, exenatide plus intensive lifestyle modifications compared with lifestyle modifications alone significantly reduced HbA1c (-1.2 versus -0.7%), FBG [-36.2 versus -16.9 mg/dl (-2.01 versus -0.94 mmol/liter)] and body weight (-6.2 versus -4.0 kg) [Apovian et al. 2010] . Two studies comparing exenatide with a SU in combination with metformin found similar decreases in HbA1c (-1.2% to −1.5% versus -1.4% to −1.8%) and FBG [-27 and −28 to −32 mg/dl (-1.5 and −1.55 to −1.77 mmol/liter)]. However, exenatide resulted in significant weight reduction while SUs were weight neutral or resulted in weight gain [Derosa et al. 2010 [Derosa et al. , 2011 . Exenatide also demonstrated greater durability than glimepiride with fewer treatment failures (41% versus 54%) and longer duration before treatment failure (180 weeks versus 142 weeks) when added to metformin [Gallwitz et al. 2012 [Nauck et al. 2009 ]. These studies suggest exenatide and liraglutide may be a better option than a SU as an add on to metformin therapy, especially in patients who are overweight or obese. In 1041 patients receiving concurrent therapy with glimepiride, liraglutide 1.2 and 1.8 mg daily were found to be superior to rosiglitazone 4 mg daily with regard to reductions in HbA1c (-1.1% versus -0.4%), FBG [-28.8 [Pratley et al. 2010] . In a 1-year extension of this trial, liraglutide maintained significant reductions in HbA1c, FBG, and body weight over sitagliptin [Pratley et al. 2011 ]. Following the extension, patients receiving sitagliptin were switched to liraglutide 1.2 or 1.8 mg daily for an additional 26 weeks and experienced additional decreases in HbA1c (-0.2 to −0.5%), FBG [-14.4 to −25.2 mg/dl (-0.8 to −1.4 mmol/liter)], and body weight (-1.6 to −2.5 kg) [Pratley et al. 2012 ].
Another study randomized 653 patients on metformin to an oral treatment strategy receiving sitagliptin 100 mg daily and an injectable treatment strategy using liraglutide 1.2 mg daily for 12 weeks. If HbA1c less than 7% was not achieved, glimepiride was added to the oral treatment strategy (47.2% patients) and liraglutide was increased to [Barnett et al. 2007 ]. In 235 patients with uncontrolled type 2 diabetes and taking two to three OAMs, exenatide 10 μg twice daily resulted in significantly more patients reaching the composite endpoint of an HbA1c less than 7.4% and weight gain up to 1 kg compared with insulin glargine (53.4% versus 19.8%) [Davies et al. 2009 ]. FBG reductions with insulin glargine may have been greater due to the titration to FBG targets; however, this titration is common in clinical practice and may better predict practical application. When added to metformin and glimepiride, liraglutide 1.8 mg daily showed significant reductions in HbA1c (-1.33% versus -1.09%) and body weight (-1.8 kg versus +1.6 kg) compared with insulin glargine. Reductions in FBG and PBG were similar between treatment groups [Russell-Jones et al 2009] . Both exenatide and liraglutide show benefit in weight loss compared with insulin glargine, but liraglutide may provide more benefit on HbA1c reductions. Exenatide has also been compared with premixed insulin aspart 70/30 (PIA) in three trials showing mixed results. Two studies found exenatide 10 μg twice daily to be noninferior to PIA with regard to reductions in HbA1c, FBG, and PBG excursions [Gallwitz et al. 2011; Nauck et al. 2007 ]. However, the third study resulted in significantly reduced HbA1c (-2.34% to −2.76% versus -1.75%) and FBG [-52.4 to −62.7 mg/dl versus -21.4 mg/dl (-2.91 to −3.48 versus -1.18 mmol/liter)] with PIA [Bergenstal et al. 2009 ]. Exenatide resulted in significant body weight reductions in all three trials compared with PIA [Gallwitz et al. 2011; Nauck et al. 2007; Bergenstal et al. 2009 ]. Based on these results, exenatide may be an appropriate option but patients requiring a larger HbA1c reduction (>2%) may require premixed insulin.
Safety
Overall, side effects were minor and rarely required discontinuation of therapy. The primary side effect of both exenatide and liraglutide was nausea, which occurred in 8-51% and 10.5-45% of patients in trials, respectively [Moretto et al. 2008; Yuan et al. 2012; Buse et al. 2004 Buse et al. , 2007 Kendall et al. 2005; DeFronzo et al. 2005; Ratner et al. 2006; Riddle et al. 2006; Liutkus et al. 2010; Zinman et al. 2007 Zinman et al. , 2009 Garber et al. 2009 ]. Nausea tended to be transient following treatment initiation and dose escalation, resolving over the first 8 weeks for exenatide and 4 weeks for liraglutide [Yuan et al. 2012; Buse et al. 2004 Buse et al. , 2007 Kendall et al. 2005; DeFronzo et al. 2005; Ratner et al. 2006; Riddle et al. 2006; Zinman et al. 2007 Zinman et al. , 2009 Garber et al. 2009; Marre et al. 2009 ]. Nausea was less persistent in patients receiving liraglutide compared with exenatide ].
Rates of hypoglycemia were relatively low, occurring in 4-12% of patients receiving exenatide and 3-12% of patients receiving liraglutide without concurrent SU [Moretto et al. 2008; Yuan et al. 2012; DeFronzo et al. 2005; Ratner et al. 2006; Buse et al. 2007; Liutkus et al. 2010; Zinman et al. 2007; Garber et al. 2009; Nauck et al. 2009 ]. Incidence of hypoglycemia with both therapies was higher in patients receiving concurrent SU therapy [Buse et al. 2004 Kendall et al. 2005; Apovian et al. 2010] . Compared with insulin, exenatide and liraglutide had lower or similar rates of overall hypoglycemia and reduced nocturnal hypoglycemia [Heine et al. 2005; Barnett et al. 2007; Davies et al. 2009; Gallwitz et al. 2011; Bergenstal et al. 2009; Russell-Jones et al. 2009 ].
Postmarketing reports of pancreatitis resulted in a black box warning (BBW) for both exenatide and liraglutide [Amylin Pharmaceuticals, Inc., 2011; Novo Nordisk A/S, 2013]. Four patients have reported pancreatitis with liraglutide in clinical trials; however, all recovered and two continued in the study [Garber et al. 2009; Nauck et al. 2009; Marre et al. 2009 ]. One patient receiving liraglutide was diagnosed with pancreatic carcinoma on day 11 of therapy; however, this was considered to be unrelated to liraglutide [Pratley et al. 2010] . Liraglutide also carries a black box warning for thyroid C-cell tumors due to occurrence in rat and mice studies. Carcinoma has not been seen in clinical trials but caution should be used in patients with a personal or family history of medullary thyroid carcinoma [Novo Nordisk A/S, 2013].
Development of antibodies occurs with both exenatide (27-49%) and liraglutide therapy (4.1-13%); however, the presence of antibodies has not affected clinical results [Moretto et al. 2008; Buse et al. 2004; Kendall et al. 2005; DeFronzo et al. 2005; Zinman et al. 2007 Zinman et al. , 2009 Marre et al. 2009; Russell-Jones et al. 2009 ]. The safety and tolerability of exenatide has been consistent across all nationalities [Lu et al. 2013; Gao et al. 2009; Kadowaki et al. 2009; Heine et al. 2005; Yang et al. 2011] .
Long-acting GLP-1 RAs
Efficacy Exenatide LAR 2 mg and albiglutide 30 and 50 mg are both dosed once weekly and have been studied as monotherapy, in combination with OAMs, and have been compared with various conventional diabetes treatment options [Amylin Pharmaceuticals, Inc., 2012; GlaxoSmithKline LLC, 2014].
Exenatide LAR monotherapy was compared with metformin, pioglitazone, and sitagliptin monotherapy in a 26-week study. HbA1c was reduced by −1.53% with exenatide LAR, -1.48% with metformin, -1.63% with pioglitazone, and −1.15% with sitagliptin from an average baseline HbA1c of 8.4-8.6%. Exenatide LAR was noninferior to metformin and superior to sitagliptin (p = 0.620 and p < 0.001, respectively), but did not reach noninferiority compared with pioglitazone (p = 0.328). Weight reductions were significantly greater with exenatide LAR compared with pioglitazone and sitagliptin but similar between exenatide once weekly and metformin [Russell-Jones et al. 2012 ].
Add-on therapy with exenatide LAR once weekly was evaluated against sitagliptin or pioglitazone in patients nonresponsive to metformin monotherapy in a 26-week randomized, double-blind trial. The baseline average HbA1c of 8.5% was reduced to 7.2% in the exenatide LAR treatment arm, 7.7% in the sitagliptin treatment arm, and 7.4% in the pioglitazone treatment arm. Reductions in HbA1c were significantly greater with exenatide LAR than sitagliptin and pioglitazone (p < 0.0001 and p = 0.0165, respectively). FBG was reduced by all treatments. Exenatide LAR had a greater reduction in FBG than sitagliptin but not pioglitazone (p = 0.0038 and p = 0.3729, respectively). Exenatide LAR also provided significant weight loss of −2.3 kg compared with −0.8 kg weight loss with sitagliptin (p = 0.0002) and the 2.8 kg weight gain with pioglitazone (p < 0.0001) ]. An extension study, in which patients were continued on exenatide LAR or switched from sitagliptin and pioglitazone to exenatide once weekly, showed sustained HbA1c, FBG, and weight reduction in the patients that continued on exenatide LAR and improved results in these parameters for patients that switched from sitagliptin and pioglitazone to exenatide LAR for up to 1 year. The most significant changes were seen in glycemic control improvement in the sitagliptin to exenatide LAR group (additional −0.3% HbA1c reduction; p = 0.0010) and in weight reduction in the pioglitazone to exenatide LAR group (-3.0 kg weight loss; p < 0.0001) [Wysham et al. 2011 ].
In a 104-week randomized, placebo and active controlled trial, albiglutide was compared with placebo, sitagliptin, and glimepiride in patients inadequately controlled on metformin. Average baseline HbA1c was 8.1%. Albiglutide provided a significantly greater reduction in HbA1c (-0.63%) than all of the other treatment arms (-0.27% with placebo, -0.28% with sitagliptin, and −0.36% with glimepiride; p < 0.001, p = 0.001, and p = 0.0033, respectively). Patients in the albiglutide group lost more weight on average but the secondary outcome of weight change from baseline to week 104 was only significantly greater in the albiglutide group compared with glimepiride [Ahren et al. 2014 ].
Exenatide LAR was compared with insulin glargine in patients with an insufficient response to metformin with or without a SU. After 26 weeks, HbA1c was significantly reduced with exenatide LAR compared with insulin glargine (-1.5 versus -1.3 respectively; p = 0.017) [Diamant et al. 2010 ]. Initial results were maintained through an 84-week extension study . A second study of exenatide LAR versus insulin detemir studied patients with an inadequate response to metformin with or without SUs. Patients were randomized to exenatide LAR 2 mg once weekly or insulin detemir once or twice daily. After 30 weeks, more participants met the primary outcome (HbA1c ≤ 7% with weight loss ≥ 1.0 kg, in the exenatide LAR group compared with the insulin detemir group (44.1% in the exenatide group versus 11.4% in the insulin detemir group, p < 0.0001) [Davies et al. 2013 ]. Additionally, there was a statistically significant change in HbA1c from baseline to week 26 among exenatide LAR users compared with insulin detemir users (-1.30 versus -0.88, respectively; p < 0.0001) [Davies et al. 2013] .
Safety
Over the 3-year follow up of the DURATION-1 study comparing exenatide LAR once weekly with exenatide twice daily, most adverse events with exenatide LAR were mild to moderate and included nausea, vomiting, diarrhea, upper respiratory tract infection, nasopharyngitis, and sinusitis [MacConell et al. 2013 ]. The incidences of nausea, vomiting, and diarrhea were highest during the first 12 weeks of exenatide LAR use and decreased to 1% during the last 12 weeks [MacConell et al. 2013] . Hypoglycemia was minor and occurred more often in patients on concomitant SU therapy than patients not treated with SUs (19.3% versus 1%, respectively). Hypoglycemia was similar with exenatide LAR compared with insulin detemir and did not lead to study drug discontinuation in any trials comparing exenatide LAR with insulin [Diamant et al. 2010; Davies et al. 2013 ].
There were no reported episodes of pancreatitis, pancreatic cancer, or thyroid cancer during the 3-year DURATION-1 study [MacConell et al. 2013] . Asymptomatic increases in pancreatic enzymes were observed in five subjects in the exenatide LAR group compared with none in the insulin glargine group at the conclusion of the DURATION-3 trial [Diamant et al. 2010 ].
Safety of exenatide LAR was studied as a primary outcome in a 26-week extension trial conducted by Onishi and colleagues . Patients from Japan originally enrolled in a 26-week study comparing the safety and efficacy of twice-daily exenatide with onceweekly exenatide LAR in an Asian population were enrolled. Patients receiving twice-daily exenatide were switched to once-weekly exenatide LAR and patients receiving exenatide LAR continued once-weekly dosing . Researchers noted that of the patients initially on twice-daily exenatide, the majority of adverse events that led to study discontinuation occurred during the first 26 weeks before the patients were switched to once-weekly exenatide LAR. Typically, adverse events such as nausea, vomiting, diarrhea, and minor hypoglycemia decreased when patients were switched from twice-daily exenatide to once-weekly exenatide LAR. Conversely, the frequency of injection-site reactions increased in patients switching from twice-daily dosing to onceweekly dosing. Adverse event rates remained consistent in patients continuing on onceweekly exenatide LAR dosing. These findings are consistent with differences noted between the safety profiles of twice-daily exenatide versus once-weekly exenatide LAR in other clinical trials .
Similar rates of adverse events have been reported in trials comparing albiglutide with conventional therapy. Nausea, diarrhea, and injection site reactions continue to be the most reported adverse events in the albiglutide treatment groups, with no increased occurrence of serious adverse events when matched to comparator treatment arms [Ahren et al. 2014; Pratley et al. 2014 ].
Comparison of short-and long-acting agents
Exenatide LAR and liraglutide were compared head to head in a 26-week study. Both agents provided clinically significant lowering in HbA1c; however, liraglutide had a statistically greater reduction in HbA1c than exenatide LAR (-1.48% versus -1.28%, respectively; p = 0.02). Additionally, the treatment difference of 0.21% [95% confidence interval (CI) 0.08-0.33] did not meet predetermined noninferiority criteria for exenatide LAR (upper limit of CI < 0.25) [Buse et al. 2013] . Liraglutide also decreased FBG and weight significantly more than exenatide LAR (p = 0.02).
Both agents had comparable improvements in cardiovascular measures such as blood pressure (BP), C-reactive protein (CRP), and lipids. Exenatide LAR had a favorable side effect profile compared with liraglutide with fewer incidences of nausea, diarrhea, and vomiting [Buse et al. 2013] .
Albiglutide was also compared with liraglutide in patients with T2DM inadequately controlled on metformin, TZD, SU, or a combination of the three in a 32-week noninferiority trial. Albiglutide lowered HbA1c but did not meet noninferiority criteria compared with liraglutide (p = 0.0846). Change in weight was also significantly greater with liraglutide (-0.62 kg with albiglutide versus -2.21 kg with liraglutide). Gastrointestinal adverse events were reported more in the liraglutide group, whereas injection site reactions were more commonly reported among the albiglutide group [Pratley et al. 2014 ].
DURATION-1, a 30-week randomized, noninferiority study, compared exenatide LAR 2 mg once weekly with exenatide 10 μg twice daily in treatment-naïve patients and patients on one or more OAMs. Although both treatment groups had significant reductions in HbA1c, greater reductions were observed in the exenatide LAR group (-1.9 versus -1.5, p = 0.0023). Both groups had similar reductions in body weight (-3.6 kg with once weekly treatment versus -3.7 kg with twice daily treatment, p = 0.89) [Drucker et al. 2008 ].
Extensions of DURATION-1 evaluated glycemic control and cardiometabolic effects at 52 weeks, 2 years, and 3 years from baseline. Patients were either continued on exenatide LAR once weekly or changed from exenatide twice daily to exenatide LAR once weekly for the duration of the extension studies. Exenatide LAR maintained initial improvements in HbA1c over the full 3 years of follow up with a change from baseline of −2.1% at 30 weeks, -2.0% at 52 weeks, -1.71% at 2 years, and −1.6% at 3 years [Buse et al. 2010; Taylor et al. 2011; MacConell et al. 2013] . Patients who were switched to once-weekly exenatide LAR had further reductions in HbA1c after the switch [Buse et al. 2010] . Body weight continued to decrease in a similar fashion between the two groups [Buse et al. 2010; Taylor et al. 2011; MacConell et al. 2013] . Patients switching from twice-daily exenatide to once-weekly exenatide LAR experienced a temporary increase in FBG for 2 weeks followed by a sharp decline in FBG levels that ultimately returned to levels similar to those prior to the switch [Buse et al. 2010 ].
Once-weekly exenatide LAR was shown to be superior to twice-daily exenatide in a 24-week open-label study in patients who were either drug naïve or previously treated with one or more OAMs and had an average HbA1c of 8.5%. The average change in HbA1c was −1.6 in the onceweekly exenatide LAR arm and −0.9 in the twicedaily exenatide arm (p < 0.0001) [Belvins et al. 2011] . A significantly greater number of patients in the once-weekly exenatide LAR group also achieved HbA1c targets of less than 7% and less than 6.5% compared with the twice-daily exenatide group (p < 0.0001 for both outcomes). Significant decreases in FBG were observed in the once-weekly treatment group compared with the twice-daily treatment group [-35 mg/dl (-1.94 mmol/liter) versus -12 mg/dl (-0.66 mmol/liter), p = 0.0008]. Reductions in body weight were significantly greater in the patients on once-weekly treatment compared with those on twice-daily treatment (-2.3 kg versus -1.4 kg, respectively; p < 0.05) [Belvins et al. 2011 ].
Ji and colleagues conducted a similar study in an Asian population. Patients were randomized to exenatide 10 μg twice daily or exenatide LAR 2 mg weekly. Again, exenatide LAR significantly lowered HbA1c compared with exenatide twice daily (-1.43 versus -1.12, p < 0.001). Exenatide LAR once weekly also significantly reduced FBG compared with twice-daily dosing [-40 .57 mg/dl (-2.25 mmol/liter) versus -23.90 mg/dl (-1.33 mmol/liter), p < 0.001]. However, significant reductions in morning and evening PBG were greater in the twice-daily dosing arm compared with the once-weekly dosing arm [-87 mg/dl (-4.83 mmol/liter) versus -63 mg/dl (-3.5 mmol/ liter), p < 0.001]. Contrary to previously published trials, a significantly greater weight loss was observed in the exenatide twice-daily dosing group compared with the exenatide LAR onceweekly dosing group (-2.45 kg and −1.63 kg, respectively; p < 0.001) [Ji et al. 2013] .
Additional benefits of GLP-1 therapy
Although results were mixed, the secondary outcomes of initial trials with exenatide and liraglutide suggested a potential benefit for cardiovascular risk factors. Exenatide 5-10 μg twice daily decreased systolic BP (SBP) by 3.5-9.4 mmHg and diastolic BP (DBP) by 0.8-4.1 mmHg [Moretto et al. 2008; Ratner et al. 2006; Buse et al. 2007; Liutkus et al. 2010; Apovian et al. 2010; Klonoff et al 2008] . A placebo-controlled trial randomized 54 patients controlled on metformin, a TZD, or both to receive exenatide 10 μg twice daily to specifically evaluate its effects on heart rate (HR) and BP. Exenatide showed no significant effect on HR or BP, although SBP was lowered by 5.6 mmHg compared with placebo [Gill et al. 2010] . Liraglutide 1.2-1.8 mg daily decreased SBP by 2.0-5.6 mmHg but tended to have no significant effect on DBP [Garber et al. 2009; Zinman et al. 2009; Marre et al. 2009; Russell-Jones et al. 2009 ]. Liraglutide 1.8 mg daily significantly reduced SBP compared with glimepiride [Garber et al. 2009; Nauck et al. 2009 ]. Exenatide LAR has also shown significant reductions in SBP and DBP [MacConell et al. 2013; Davies et al. 2013] . Some studies have seen significant improvement in low-density lipoprotein (LDL) [Buse et al. 2004; Klonoff et al. 2008; Zinman et al. 2009 ], triglycerides (TGs) [Ratner et al. 2006; Klonoff et al. 2008; Zinman et al. 2009 ], high-density lipoprotein (HDL) [Ratner et al. 2006; Klonoff et al. 2008] , and apolipoprotein B (ApoB) [Buse et al. 2004; Ratner et al. 2006 ] with exenatide and liraglutide but others found no significant effects on lipids [Moretto et al. 2008; DeFronzo et al. 2005; Liutkus et al. 2010] . Post hoc analysis of the DURATION-1 study revealed improvements in ApoB, ApoB/ ApoA1, TGs, LDL4-C, and HDL2-C with exenatide LAR (p <0.05) compared with significant changes in TGs and very-low-density lipoprotein with twice-daily exenatide (p < 0.05) [Chiquette et al. 2012] . Over the 3-year follow up of the DURATION-1 study population, significant reductions in DBP, total cholesterol, LDL, and TGs were maintained throughout the 3-year follow up [MacConell et al. 2013 ]. The first longterm phase IV trial evaluating cardiovascular outcomes in patients on exenatide LAR compared with usual care without exenatide is underway to evaluate a composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke over a 7.5-year follow up [ClinicalTrials. gov identifier: NCT01144338].
Initial studies of both exenatide and liraglutide found improvements in β-cell function and insulin sensitivity based on Homeostasis Model Assessment HOMA-B [Moretto et al. 2008; Buse et al. 2007; Liutkus et al. 2010; Zinman et al. 2007; Klonoff et al. 2008; Derosa et al. 2012; Zinman et al. 2009; Nauck et al. 2009; Marre et al. 2009; Pratley et al. 2010] and HOMA-S values [Buse et al. 2007] as monotherapy and in combination with metformin, SUs, or TZDs. Compared with exenatide, liraglutide had significantly greater improvements in β-cell function ]. Compared with SUs, exenatide and liraglutide demonstrated significant improvements in insulin resistance (based on HOMA-IR) [Derosa et al. 2011; Garber et al. 2009 Garber et al. , 2011 and β-cell function (based on HOMA-B) [Derosa et al. 2010] whereas therapy with SUs did not [Derosa et al. 2010 [Derosa et al. , 2011 Garber et al. 2009 ]. In a 3-year study, exenatide significantly improved β-cell function based on disposition index. When exenatide was discontinued for 4 weeks after 1 year, β-cell function returned to baseline; however, after 3 years of therapy β-cell function remained elevated after exenatide discontinuation, suggesting long-term treatment may result in longstanding effects on βcell function [Bunck et al. 2011] .
Early studies of exenatide found evidence to suggest exenatide may decrease liver enzymes, aspartate aminotransferase and alanine aminotransferase (ALT), especially in patients with elevated baseline levels [Buse et al. 2007; Klonoff et al. 2008] , which may suggest benefits for patients with liver impairment. In a study of 24 patients with T2DM on diet or metformin therapy, hepatic fat content was significantly reduced in patients randomized to receive a combination of pioglitazone and exenatide compared with pioglitazone alone (-4.5% versus 7.4%; p < 0.001). ALT was also significantly reduced with combination therapy [Sathyanarayana et al. 2011] . These results suggest a potential benefit in patients with liver impairment or high liver fat content.
Secondary endpoints of early trials suggested significant improvement in inflammatory markers, including tumor necrosis factor α and CRP with exenatide twice daily and once-weekly therapy [Derosa et al. 2010 [Derosa et al. , 2011 Chiquette et al. 2012; Davies et al. 2013] . A 16-week study also found a decrease in CRP with exenatide compared with placebo (-0.2 mg/liter versus +0.8 mg/liter) [Wu et al. 2011] . In a placebo-controlled trial, 174 patients with T2DM uncontrolled on metformin were randomized to exenatide 10 μg twice daily or placebo. After 1 year of therapy, exenatide plus metformin significantly reduced resistin levels but not vaspin or chemerin compared with placebo [Derosa et al. 2013] . The clinical implications of these changes are not known.
GLP-1 RAs in development
Four additional GLP-1 RAs, taspoglutide, lixisenatide, dulaglutide, and semaglutide are currently in development. Add-on therapy with taspoglutide 10 mg and 20 mg once weekly was compared with TZDs and basal insulin in patients whose condition was uncontrolled on metformin with or without a SU Pratley et al. 2013] . Taspoglutide 20 mg weekly was found to be noninferior to pioglitazone and insulin glargine, with average reduction in HbA1c of −1.36 and −0.98, respectively Pratley et al. 2013] . Compared with exenatide twice daily and sitagliptin in patients whose condition is inadequately controlled on metformin with or without a TZD, taspoglutide 20 mg weekly reduced HbA1c and FBG to a significantly greater extent (p < 0.0001) Rosenstock et al. 2013a ]. However, gastrointestinal disorders and injection-site reactions have been observed more frequently in the taspoglutide treatment arm of several phase III clinical trials, leading to a higher withdrawal rate among participants Pratley et al. 2013; Bergenstal et al. 2012; Rosenstock et al. 2013a ]. The negative side-effect profile seen in clinical trials led to the discontinuation of phase III trials of taspoglutide. The product is now under investigation for reformulation by the company Ipsen, Basking Ridge, NJ [Rosenstock et al. 2013a ].
Lixisenatide is available in Europe, Mexico, Australia, and Japan as the brand name Lyxumia; however, the US FDA new drug application was recently withdrawn by the manufacturer [Sanofi, 2013, Bridgewater, NJ] . Lixisenatide had positive results in HbA1c, FBG, and weight reductions compared with placebo in patients whose condition was uncontrolled on metformin with or without a SU [Bolli et al. 2014; Rosenstock et al. 2014 ]. The manufacturer, Sanofi, plans to resubmit the application to the US FDA after the current cardiovascular outcomes trial, ELIXA, has concluded [Sanofi, 2013] .
Dulaglutide has been studied against placebo and conventional therapy options in several clinical trials. Dulaglutide 1.5 mg and 0.75 mg weekly provided significant reductions in HbA1c over 26 weeks compared with placebo. Dulaglutide monotherapy was also compared with metformin monotherapy and was found to be noninferior to metformin for HbA1c lowering, with no differences in side-effect profile and weight reduction. Dulaglutide was also shown to be noninferior to sitagliptin in HbA1c reduction from baseline to 52 weeks [Lilly, 2013] . Several trials are still underway comparing dulaglutide with insulin glargine and evaluating cardiovascular outcomes with dulaglutide use.
Semaglutide is an investigational once-weekly GLP-1 RA. In a dose-finding, phase II trial, semaglutide 0.8 mg and 1.6 mg once weekly produced greater reductions in HbA1c at 12 weeks than liraglutide 1.2 mg and 1.8 mg daily and greater weight reductions compared with placebo. Participant withdrawals were related to gastrointestinal adverse events . A phase II pharmacokinetic study in subjects with or without renal impairment suggested dose adjustment may not be needed for patients with renal insufficiency, although more studies are needed [Marbury et al. 2014] . Semaglutide is currently undergoing phase III trials.
Place in therapy
All four FDA-approved GLP-1 RAs, exenatide, liraglutide, exenatide LAR, and albiglutide, have demonstrated efficacy in regard to glycemic control with significant reductions in HbA1c, FBG, and PBG both as monotherapy and in combination with common first-and second-line agents. HbA1c reductions ranged from 0.5% to 1.8%, indicating GLP-1 RAs are most appropriate in patients with an HbA1c less than 9% in order to reach HbA1c targets. Long-acting GLP-1 RAs seem to be superior in glycemic control compared with exenatide but not compared with liraglutide.
Only exenatide and liraglutide are currently approved and have been shown to provide additional lowering of PBG for use in combination with long-acting insulin. Long-acting GLP-1 RAs still require additional studies to determine if benefit is seen. Body weight reductions were also significant with all GLP-1 RAs, which may make them a superior option for patients who are overweight or obese compared with treatments which may increase weight, including SUs, TZDs, and insulin. In general, GLP-1 RAs were well tolerated with most adverse effects being mild and gastrointestinal in nature. Nausea was the most common adverse effect and tended to resolve after the first weeks of treatment. Incidence of nausea was lower and less persistent in longeracting agents. All agents carry a warning for the potential to cause pancreatitis. In patients with a history of pancreatitis, other options may be more prudent. Liraglutide, exenatide LAR, and albiglutide all carry a BBW for C-cell thyroid tumors. These agents should not be used in patients with a personal or family history of medullary thyroid carcinoma. Given the increased risk of cardiovascular disease with diabetes, the effects of medications on CV risk factors should be considered.
While studies have suggested potential benefits on BP, lipids, and inflammatory markers with GLP-1 RAs, larger trials are needed to determine the clinical relevance of these effects.
Conclusion
GLP-1 RAs provide improved glycemic control and weight reduction along with a good safety profile. The addition of GLP-1 RAs may be considered in patients not tolerating first-line medications, patients receiving metformin, a SU, a TZD, or insulin therapy and not meeting glycemic goals, or patients in need of weight loss. and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther 230: 1448-1460. Nauck, M., Baller, B. and Meier, J. (2004) Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53: S190-S196.
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